Tertiary lymphoid structures and B lymphocytes: a promising therapeutic strategy to fight cancer.
B cells
TLS modulation
adaptive anti-tumor response
immunotherapy
tertiary lymphoid structures
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
30
05
2023
accepted:
24
07
2023
medline:
28
8
2023
pubmed:
25
8
2023
entrez:
25
8
2023
Statut:
epublish
Résumé
Tertiary lymphoid structures (TLSs) are clusters of lymphoid cells with an organization that resembles that of secondary lymphoid organs. Both structures share common developmental characteristics, although TLSs usually appear in chronically inflamed non-lymphoid tissues, such as tumors. TLSs contain diverse types of immune cells, with varying degrees of spatial organization that represent different stages of maturation. These structures support both humoral and cellular immune responses, thus the correlation between the existence of TLS and clinical outcomes in cancer patients has been extensively studied. The finding that TLSs are associated with better prognosis in some types of cancer has led to the design of therapeutic strategies based on promoting the formation of these structures. Agents such as chemokines, cytokines, antibodies and cancer vaccines have been used in combination with traditional antitumor treatments to enhance TLS generation, with good results. The induction of TLS formation therefore represents a novel and promising avenue for the treatment of a number of tumor types.
Identifiants
pubmed: 37622111
doi: 10.3389/fimmu.2023.1231315
pmc: PMC10445545
doi:
Substances chimiques
Antibodies
0
Cancer Vaccines
0
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1231315Informations de copyright
Copyright © 2023 Esparcia-Pinedo, Romero-Laorden and Alfranca.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Cancer Gene Ther. 2013 Aug;20(8):469-77
pubmed: 23846252
J Clin Oncol. 2008 Sep 20;26(27):4410-7
pubmed: 18802153
Immunol Rev. 2010 Jan;233(1):267-85
pubmed: 20193005
Front Immunol. 2018 Sep 12;9:1952
pubmed: 30258435
Clin Dev Immunol. 2013;2013:271246
pubmed: 24371445
Cancer Cell. 2023 Mar 13;41(3):466-489
pubmed: 36917951
Nature. 2011 Nov 13;479(7374):542-6
pubmed: 22080953
Sci Immunol. 2020 Apr 10;5(46):
pubmed: 32276965
Cancers (Basel). 2011 Dec 28;4(1):1-10
pubmed: 24213222
Polymers (Basel). 2020 Nov 16;12(11):
pubmed: 33207715
Immunity. 2001 Feb;14(2):111-21
pubmed: 11239444
J Exp Med. 2009 Oct 26;206(11):2339-49
pubmed: 19808255
Cancers (Basel). 2021 Aug 23;13(16):
pubmed: 34439387
Nat Commun. 2019 Sep 13;10(1):4186
pubmed: 31519915
Mod Pathol. 2018 Jun;31(6):910-922
pubmed: 29416107
Nat Commun. 2021 Feb 10;12(1):935
pubmed: 33568675
Oncoimmunology. 2020 Apr 7;9(1):1747339
pubmed: 32313726
Science. 1994 Apr 29;264(5159):703-7
pubmed: 8171322
Cancers (Basel). 2020 Sep 16;12(9):
pubmed: 32947928
Semin Immunol. 2008 Feb;20(1):26-42
pubmed: 18243731
Nature. 2017 Nov 16;551(7680):340-345
pubmed: 29144460
Nat Med. 1998 May;4(5):627-30
pubmed: 9585241
Nat Rev Cancer. 2019 Jun;19(6):307-325
pubmed: 31092904
Front Immunol. 2020 May 15;11:922
pubmed: 32499782
J Clin Invest. 2001 Dec;108(12):1771-80
pubmed: 11748260
Cancer Immunol Immunother. 2019 Jan;68(1):109-120
pubmed: 30315348
J Exp Med. 2021 Jan 4;218(1):
pubmed: 33601413
Nat Med. 2020 Dec;26(12):1839-1844
pubmed: 33046870
Cardiovasc Res. 2014 Mar 1;101(3):434-43
pubmed: 24272771
Clin Cancer Res. 2017 Aug 15;23(16):4556-4568
pubmed: 28468947
Nat Biotechnol. 2004 Dec;22(12):1539-45
pubmed: 15568019
J Clin Oncol. 2006 Dec 1;24(34):5373-80
pubmed: 17135638
Cancer Res. 2014 Feb 1;74(3):705-15
pubmed: 24366885
Sci Transl Med. 2017 Apr 12;9(385):
pubmed: 28404866
Cell. 2019 Nov 14;179(5):1191-1206.e21
pubmed: 31730857
Am J Respir Crit Care Med. 2013 Nov 1;188(9):1126-36
pubmed: 24093638
J Immunol. 2013 Oct 15;191(8):4141-51
pubmed: 24043896
Nature. 2021 Mar;591(7850):464-470
pubmed: 33536615
Nature. 2020 Jan;577(7791):549-555
pubmed: 31942075
Cancers (Basel). 2020 May 14;12(5):
pubmed: 32422889
Cancer Res. 2011 Oct 15;71(20):6391-9
pubmed: 21900403
Immunity. 2017 Aug 15;47(2):349-362.e5
pubmed: 28801233
Nature. 2020 Jan;577(7791):556-560
pubmed: 31942077
Nat Commun. 2021 Apr 12;12(1):2186
pubmed: 33846305
Hum Pathol. 2013 Aug;44(8):1569-76
pubmed: 23465276
Oncoimmunology. 2017 Apr 28;6(6):e1322238
pubmed: 28680760
Oncotarget. 2015 Oct 20;6(32):33486-99
pubmed: 26378021
Nat Med. 2020 Dec;26(12):1845-1851
pubmed: 33046869
Biomed J. 2021 Apr;44(2):123-132
pubmed: 33849806
J Biol Chem. 2000 May 12;275(19):14307-15
pubmed: 10799510
Front Immunol. 2017 Dec 19;8:1830
pubmed: 29312327
Immunol Rev. 2002 Nov;189:41-50
pubmed: 12445264
J Pathol. 2018 Jun;245(2):209-221
pubmed: 29603739
Sci Transl Med. 2014 Jan 29;6(221):221ra13
pubmed: 24477000
Cancer Immunol Immunother. 2000 Jan;48(10):541-9
pubmed: 10630306
Afr Health Sci. 2020 Sep;20(3):1264-1272
pubmed: 33402974
Nat Commun. 2016 Feb 01;7:10346
pubmed: 26831747
Front Immunol. 2018 Nov 20;9:2660
pubmed: 30515157
Cancer Immunol Immunother. 2011 Dec;60(12):1729-38
pubmed: 21779876
J Clin Invest. 2013 Jul;123(7):2873-92
pubmed: 23778140
Int J Cancer. 2018 Jul 1;143(1):167-178
pubmed: 29417587
Immunity. 2011 Dec 23;35(6):986-96
pubmed: 22177922
J Clin Oncol. 2007 Jun 20;25(18):2586-93
pubmed: 17577038
Front Immunol. 2021 Jun 24;12:675146
pubmed: 34248957
J Hepatol. 2022 Mar;76(3):608-618
pubmed: 34793865
Front Immunol. 2016 Aug 16;7:312
pubmed: 27579026
Clin Transl Oncol. 2007 Nov;9(11):694-702
pubmed: 18055324
Cancer Immunol Immunother. 2007 Sep;56(9):1459-69
pubmed: 17279413
Cancer Res. 2006 Mar 15;66(6):3205-13
pubmed: 16540672
J Clin Invest. 2013 Apr;123(4):1457-74
pubmed: 23454746
Front Immunol. 2021 Mar 08;12:626776
pubmed: 33763071
J Immunother Cancer. 2020 Sep;8(2):
pubmed: 32900863
Biomaterials. 2016 Apr;84:210-218
pubmed: 26828685
Clin Cancer Res. 2017 Jan 1;23(1):250-262
pubmed: 27354470
Nat Rev Immunol. 2009 May;9(5):353-63
pubmed: 19365408
Breast Cancer. 2019 Mar;26(2):180-189
pubmed: 30244409
Cancer Res. 2001 Dec 15;61(24):8794-802
pubmed: 11751401
J Immunol. 2002 Jul 1;169(1):424-33
pubmed: 12077273
Nat Rev Immunol. 2003 Apr;3(4):292-303
pubmed: 12669020
Cell. 2020 Mar 19;180(6):1081-1097.e24
pubmed: 32142650
Nat Protoc. 2017 Jan;12(1):168-182
pubmed: 28005068
Cancer Immunol Res. 2019 Jul;7(7):1091-1105
pubmed: 31164356
Cell Rep. 2020 Jan 21;30(3):714-724.e5
pubmed: 31968248
Oncoimmunology. 2016 Jan 04;5(5):e1123370
pubmed: 27467936
Nat Med. 2022 Jun;28(6):1199-1206
pubmed: 35618839
Exp Dermatol. 2017 May;26(5):402-408
pubmed: 27673278
Front Immunol. 2017 May 17;8:563
pubmed: 28567040
Sci Rep. 2018 May 18;8(1):7861
pubmed: 29777158
Cancer Immunol Res. 2014 Jul;2(7):616-31
pubmed: 24942756
Front Immunol. 2017 Aug 25;8:1029
pubmed: 28970832
Immunol Rev. 2017 Nov;280(1):149-164
pubmed: 29027226
J Exp Med. 2003 May 5;197(9):1191-8
pubmed: 12732660
J Immunol. 2016 Aug 15;197(4):1231-41
pubmed: 27421476
Nat Med. 2004 Sep;10(9):942-9
pubmed: 15322536
J Hepatol. 2019 Jan;70(1):58-65
pubmed: 30213589
Clin Exp Immunol. 2010 Jul 1;161(1):81-8
pubmed: 20408858
Trends Immunol. 2002 Nov;23(11):549-55
pubmed: 12401408
Cancer Res. 2012 Aug 15;72(16):3997-4007
pubmed: 22850419
Tumour Biol. 2016 May;37(5):6581-8
pubmed: 26638169
Cancer Res. 2011 May 15;71(10):3505-15
pubmed: 21444674
Nat Commun. 2021 Aug 26;12(1):5137
pubmed: 34446728
Front Immunol. 2021 May 26;12:648812
pubmed: 34122408
JCI Insight. 2019 Aug 13;5:
pubmed: 31408436
J Exp Med. 2009 Jan 16;206(1):35-41
pubmed: 19114665
Semin Immunol. 2020 Apr;48:101406
pubmed: 33248905
Front Immunol. 2016 Nov 08;7:477
pubmed: 27877173
Curr Biol. 2020 Aug 17;30(16):R921-R925
pubmed: 32810447
Front Immunol. 2021 Aug 10;12:713704
pubmed: 34447380
J Immunol. 2010 Jul 1;185(1):717-28
pubmed: 20525884
Ann Oncol. 2018 Aug 1;29(8):1853-1860
pubmed: 29982279
Cancer Cell. 2016 Sep 12;30(3):500
pubmed: 27622338
Nature. 2020 Jan;577(7791):561-565
pubmed: 31942071
Immunity. 2022 Mar 8;55(3):527-541.e5
pubmed: 35231421
Cell Rep. 2017 Mar 28;18(13):3078-3090
pubmed: 28355561
Nat Immunol. 2015 Dec;16(12):1235-44
pubmed: 26502405
Cell Death Dis. 2022 Jul 13;13(7):607
pubmed: 35831283
Front Immunol. 2016 Aug 22;7:316
pubmed: 27597851
Proc Natl Acad Sci U S A. 2019 May 21;116(21):10453-10462
pubmed: 31076558
J Clin Invest. 2021 Oct 1;131(19):
pubmed: 34411002
Cancer Res. 2018 Mar 1;78(5):1308-1320
pubmed: 29279354
Immunol Rev. 2016 May;271(1):260-75
pubmed: 27088920
Oncoimmunology. 2017 Dec 18;7(2):e1378844
pubmed: 29416939
Oncoimmunology. 2012 Aug 1;1(5):789-790
pubmed: 22934284
Science. 2022 Jan 07;375(6576):eabf9419
pubmed: 34990248
Gut. 2017 Feb;66(2):342-351
pubmed: 26669617
Immunity. 2015 Sep 15;43(3):579-90
pubmed: 26341400
Oncology. 2005;69 Suppl 3:4-10
pubmed: 16301830
Am J Pathol. 2000 Apr;156(4):1133-8
pubmed: 10751336
Cell. 2021 Dec 9;184(25):6101-6118.e13
pubmed: 34852236
Sci Rep. 2012;2:765
pubmed: 23097687
Immunol Rev. 2008 Jun;223:186-201
pubmed: 18613837
J Immunol. 2010 Apr 1;184(7):4006-16
pubmed: 20194720
Front Oncol. 2018 Jul 09;8:256
pubmed: 30038899
Nat Cancer. 2021 Aug;2(8):794-802
pubmed: 35118423
Cell. 2022 Mar 31;185(7):1208-1222.e21
pubmed: 35305314
Front Immunol. 2022 May 19;13:868155
pubmed: 35664009
Nat Rev Clin Oncol. 2022 Jul;19(7):441-457
pubmed: 35365796
Clin Cancer Res. 2020 Aug 1;26(15):4018-4030
pubmed: 32332015
Am J Respir Crit Care Med. 2014 Apr 1;189(7):832-44
pubmed: 24484236
Front Immunol. 2016 Oct 03;7:407
pubmed: 27752258
Am J Pathol. 2011 Jul;179(1):37-45
pubmed: 21703392
Cancer Metastasis Rev. 2010 Jun;29(2):309-16
pubmed: 20405169
PLoS One. 2009 Sep 23;4(9):e7142
pubmed: 19774076
Trends Immunol. 2012 Jun;33(6):297-305
pubmed: 22622061
Immunol Rev. 2021 Jul;302(1):184-195
pubmed: 34060101
J Cancer. 2020 Jan 14;11(6):1568-1583
pubmed: 32047563
Genome Biol. 2020 Jun 24;21(1):152
pubmed: 32580738
J Clin Invest. 2007 Apr;117(4):997-1007
pubmed: 17364025
Oncoimmunology. 2018 Nov 2;8(1):e1512458
pubmed: 30546950
Nat Immunol. 2017 Nov;18(11):1207-1217
pubmed: 28892469
Theranostics. 2017 Sep 26;7(18):4383-4398
pubmed: 29158834
Oncoimmunology. 2015 Apr 02;4(3):e974374
pubmed: 25949892
Clin Cancer Res. 2012 Jun 15;18(12):3281-92
pubmed: 22553348
Br J Cancer. 2015 May 26;112(11):1782-90
pubmed: 25942397
Cell. 2015 Sep 10;162(6):1257-70
pubmed: 26343581
Cell Mol Life Sci. 2022 Jun 11;79(7):359
pubmed: 35689679